Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D08JGB
|
|||
| Drug Name |
Otlertuzumab
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 2 | [1], [2], [3] | |
| Peripheral T-cell lymphoma [ICD-11: 2A90.C; ICD-10: C84.4; ICD-9: 202.7] | Phase 2 | [1] | ||
| Company |
Aptevo Therapeutics Seattle, WA
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte antigen CD37 (CD37) | Target Info | Inhibitor | [1], [2] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.